Omkar Speciality Chemicals Limited Reports Q2 FY19 Results

Deepthi | Myequity news | Date : 01-12-2018 19:10:00 IST

Omkar Speciality Chemicals Limited (OSCL) announced its standalone financial results for the second quarter ending September 30, 2018. These results were taken on record by the Board of Directors at a meeting held in Mumbai on November 14, 2018.


• Revenue from Operations at Rs.10.02 crore
• Domestic Sales at Rs.5.47, and Export Sales at Rs.4.55 crore
• Gross Margin at Rs. 4.34 to 43.25 percent as compared to Rs.1.59 crore during Q1FY19
• EBITDA (before exceptional items) in positive trajectory at Rs 0.41 crore

“Our EBITDA (before exceptional items) margins have improved during Q2FY19. It currently stands at Rs 0.41 crore with an increase of 4.11 percent as compared to ‐16.27 percent during Q1FY19”, said Mr. Pravin S. Herlekar, Chairman and Managing Director, Omkar Speciality Chemicals Limited (OSCL). “The improvement in our gross margin was on account of our focus on development of Next‐Gen niche molecules with high EBITDA margins. This led to a noticeable improvement in our overall working capital cycle. Besides, our past R&D efforts have also helped us in reaping benefits, as compared to last couple of quarters.”


Incorporated in 1983, Omkar Speciality Chemicals Ltd (OSCL) is a vertically integrated group spanning the entire speciality chemicals and pharma value chain, with established credentials in innovation of complex chemistry, and is a pioneer in various niche molecules. The group is primarily engaged in the production of specialty chemicals and pharma intermediates. It manufactures a range of organic, inorganic and organo inorganic intermediates that find application in various industries, such as pharmaceuticals, chemicals, glass, cosmetic ceramic and poultry feeds.

More from Myequity